The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

References

• Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. 2016;7:19620–30. doi:10.18632/oncotarget.7746. PMID:26934000.
   PubMed Web of Science ®Google Scholar
• Henson E, Chen Y, Gibson S. EGFR family members' regulation of autophagy is at a crossroads of cell survival and death in cancer. Cancers (Basel). 2017;9(4). pii: E27. doi:10.3390/cancers9040027.
   Web of Science ®Google Scholar
• Appert-Collin A, Hubert P, Crémel G, Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front Pharmacol. 2015;6:283 doi:10.3389/fphar.2015.00283. PMID:26635612.
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303 doi:10.1016/j.ccr.2014.02.025. PMID:24651011.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 2017 IN PRESS;8(52):90262–90277 doi:10.18632/oncotarget.21660. PMID:29163826.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2017.
   Web of Science ®Google Scholar
• Booth L, Roberts JL, Kirkwood J, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration. Oncotarget. 2017. doi:10.18632/oncotarget.23681.
   Google Scholar
• Zhang Y, Zhang J, Liu C, Du S, Feng L, Luan X, Zhang Y, Shi Y, Wang T, Wu Y, Cheng W, Meng S, Li M, Liu H. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016;382:176–185. doi:10.1016/j.canlet.2016.08.026. PMID:27597738.
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293–301. doi:10.1038/nrc2812. PMID:20200537.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917 doi:10.1038/nature03443. PMID:15829966.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921 doi:10.1038/nature03445. PMID:15829967.
   PubMed Web of Science ®Google Scholar
• Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev. 2008;18:80–86 doi:10.1016/j.gde.2008.01.016. PMID:18343102.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–244. doi:10.1016/S0140-6736(10)60892-6. PMID:20609467.
   PubMed Web of Science ®Google Scholar
• Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016;12:1439–56. doi:10.2217/fon-2016-0002. PMID:27087632.
   PubMed Web of Science ®Google Scholar
• McLachlan J, George A, Banerjee S. The current status of PARP inhibitors in ovarian cancer. Tumori. 2016;102:433–440 doi:10.5301/tj.5000558. PMID:27716873.
   PubMed Web of Science ®Google Scholar
• Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol. 2012;82:322–32. doi:10.1124/mol.112.078907. PMID:22596349.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Dent P. [pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells. Cancer Biol Ther. 2017. doi:10.1080/15384047.2017.1362511.
   Web of Science ®Google Scholar
• Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8:16367–16386. doi:10.18632/oncotarget.14829. PMID:28146421.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget. 2017;8:1449–1468. doi:10.18632/oncotarget.13640. PMID:27903966.
   PubMedGoogle Scholar
• Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983;43:5379–89. PMID:6604576.
   PubMed Web of Science ®Google Scholar
• Morimoto H, Safrit JT, Bonavida B. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol. 1991;147:2609–16. PMID:1918981.
   PubMed Web of Science ®Google Scholar
• Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nuñez G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002;62:924–31. PMID:11830553.
   PubMed Web of Science ®Google Scholar
• Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Hum Cell. 2017;30:226–236. doi:10.1007/s13577-017-0162-1. PMID:28251557.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly (ADP-ribose) polymerase inhibitor niraparinib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882–92. doi:10.1016/S1470-2045(13)70240-7. PMID:23810788.
   PubMed Web of Science ®Google Scholar
• Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016;12:947–57. doi:10.1080/17425255.2016.1198317. PMID:27284682.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang Y, Yao Y, Li W, Lai Q, Li J, Zhou Y, Kang T, Xie Y, Wu Y, Chen X, Yi C, Gou L, Yang J. Eradication of growth of HER2-Positive ovarian cancer with Trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse Xenograft Model. Int J Gynecol Cancer 2014;24:1158Y1164. doi:10.1097/IGC.0000000000000179.
   Web of Science ®Google Scholar
• Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4:1592–605. doi:10.18632/oncotarget.1148. PMID:24009064.
   PubMed Web of Science ®Google Scholar
• Miao LJ, Huang FX, Sun ZT, Zhang RX, Huang SF, Wang J. Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in non-small cell lung cancer cells. Tumour Biol. 2014;35:7097–103. doi:10.1007/s13277-014-1961-6. PMID:24760274.
   PubMedGoogle Scholar
• Jiang Q, Wang Y, Li T, Shi K, Li Z, Ma Y, Li F, Luo H, Yang Y, Xu C. Heat shock protein 90-mediated inactivation of nuclear factor-κB switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells. Mol Biol Cell. 2011;22:1167–80 doi:10.1091/mbc.E10-10-0860. PMID:21346199.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen S, Gou WF, Xiao LJ, Takano Y, Zheng HC. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma. Tumour Biol. 2014;35:1955–64. doi:10.1007/s13277-013-1261-6. PMID:24132590.
   PubMed Web of Science ®Google Scholar
• Ji D, Zhang Z, Cheng L, Chang J, Wang S, Zheng B, Zheng R, Sun Z, Wang C, Zhang Z, Liu R, Zhang X, Liu X, Wang X, Li J. The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. PLoS One. 2014;9:e85116. doi:10.1371/journal.pone.0085116. PMID:24416349.
   PubMed Web of Science ®Google Scholar